Medical News
Major Adverse Cardiac Events in Symptomatic Women with Non-o...
Int J Cardiovasc Imaging.
Symptomatic women with non-obstructive CAD on coronary CTA are at higher risk for MACE, with the ASCVD risk score...
14 Oct 2021
Empagliflozin in Heart Failure with a Preserved Ejection Fra...
New Engl J Med.
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients...
14 Oct 2021
Association of Blood Pressure, Its Treatment, and Treatment...
Hypertension.
Our results suggest that WMHs represent a marker of advanced hypertension pathology. Hence, early treatment should...
13 Oct 2021
On-Treatment Blood Pressure and Cardiovascular Outcomes in A...
J AM Coll Cardiol.
In adults with hypertension and LVH, the risk for CVD events was the lowest at SBP <130 mm Hg and DBP <80 mm...
12 Oct 2021
eCMEs
Key Trials
Metabolically Healthy Obesity and its Association with Obesity-related Outcomes
Individuals with metabolically healthy obesity are at a substantially higher risk of obesity-related outcomes as compared with individuals with...
FIGARO-DKD: Impact of Finerenone on CV Outcomes in Patients with T2DM and CKD
The FIGARO-DKD trial demonstrated that as compared with placebo, treatment with finerenone improved the CV outcomes in patients with T2DM and CKD.
GALACTIC-HF: The Therapeutic Benefits of Omecamtiv Mecarbil Increase with decreasing Ejection Fraction in HFrEF Patients
The subgroup analysis of the GALACTIC-HF trial demonstrates that the therapeutic benefits of omecamtiv mecarbil increase progressively with the...
COMPASS: Rivaroxaban Plus Aspirin reduces the Death Risk vs. Aspirin alone in Patients with Chronic CAD and PAD
This sub-analysis of the COMPASS trial demonstrated that patients with chronic CAD or PAD treated with rivaroxaban-aspirin combination had a reduced...
Slide Library
Medical Management Strategy of CTEPH: Role of Riociguat
Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH
Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...
Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...
Diabetic Dyslipidemia
Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...
Our Publications
CARLOC-I (Carvedilol +Ivabradine) Monograph
Carvedilol/ivabradine have a proven chemical-pharmaceutical quality and are considered an approvable fixed-dose combination. Both carvedilol and...
Rivazest (Rivaroxaban) Monograph
Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...
Telyse (Tenecteplase) Monograph
In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....
Mexiletine FAQ Booklet
Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...
Patient Education
Understanding Angioplasty
Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.
Understanding Obesity
This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss.
Hypertension
Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure.
.jpg)
Poll
What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
20-40%
40-50%
50-70%
70-80%
Almost all
Total votes: 28